Sunrun Inc vs Zoetis Inc — how do they compare? Sunrun Inc trades at $11.45 (market cap $2.73B), while Zoetis Inc trades at $76.07 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 11.7× Sunrun Inc's market cap, and Zoetis Inc pays a 2.78% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals.
| RUN | ZTS | |
|---|---|---|
Market Cap | $2.73B | $31.95B |
Sector | Technology | Health |
52-Week High | $21.41 | $156.76 |
52-Week Low | $9.07 | $71.91 |
Enterprise Value | $16.92B | $39.24B |
Dividend Yield | — | 2.78% |
Signals from Pluang's Aura AI — not financial advice
Sunrun (RUN) trades at $11.44, down 3.46% today, with a bearish technical outlook. The stock shows strong profitability with a 17.88% net income margin and trades at a low P/E of 5.56. Recent news highlights a major partnership with Tesla and Renew Home for a 16-gigawatt virtual power plant, boosting growth prospects. Earnings have consistently beaten estimates, with Q1 2026 EPS of $0.62 versus -$0.05 expected.
The outlook is mixed: analyst consensus is bullish with a $16.27 price target, but cash flow concerns and high debt-to-asset ratio of 70.76% pose risks. The partnership with Tesla offers significant upside in the AI-driven energy demand sector, yet execution and financing challenges remain key hurdles for sustained growth.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →